With a market capitalization (market cap) of $3.18B — a measure of how much the company is worth — Pulse Biosciences, Inc. is the 1763rd most valuable company in Healthcare as of August 18, 2026. Shares trade at $46.00, down +1.69% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Visit websiteAs of August 18, 2026, Pulse Biosciences, Inc. (PLSE) is worth $3.18B — this is its market capitalization, the total value of all its outstanding shares.
Pulse Biosciences, Inc.’s market cap is $3.18B, which ranks it #1763 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Pulse Biosciences, Inc. (PLSE) shares trade at $46.00, down 1.69% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025